Exact Sciences


Exact Sciences Falls 4% On Larger-Than-Feared 4Q Loss

Shares of Exact Sciences Corporation fell 4.4% In Tuesday’s post-market trading after the cancer screening and diagnostic tests provider reported lower-than-expected 4Q earnings.

Exact Sciences Reports 63% Reduction For Cologuard Testing in April

Exact Sciences (EXAS) has pre-announced first quarter results, with total revenue up 114% year-over-year at $348 million, surpassing the Street estimate of $342.6 …

Canaccord Boosts Price Target on Exact Sciences (EXAS) as Pfizer Deal Marks Upside to the Top Line

Shares of molecular diagnostics company Exact Sciences (NASDAQ:EXAS) rose by double digits today on heavy volume, thanks to a new U.S.

Transenterix Inc (TRXC) Earns a Price Target Jump, EXACT Sciences Corporation (EXAS) Business Poised to Take Off Within 3 Years

Rick Wise: High surgeon intrigue in TRXC’s Senhance; Mark Massaro: EXAS could hit 2.7M in tests by 2021.

Canaccord Boosts Price Target For Exact Sciences Corporation Following Positive Coverage Decision By Anthem

In a research report published Friday, Canaccord Genuity analyst Mark Massaro reiterated a Buy rating on EXACT Sciences Corporation (NASDAQ:EXAS) and raised the price target …

Canaccord Maintains Buy On Exact Sciences Corporation; Here’s Why

In a research report issued this morning, Canaccord Genuity analyst Mark Massaro maintained a Buy rating on EXACT Sciences Corporation (NASDAQ:EXAS) with a $27 price …

UPDATE: Exact Sciences Corporation Price Target Downgraded At Canaccord

In a research report released today, Canaccord Genuity analyst Mark Massaro reiterated a Buy rating on Exact Sciences Corporation (NASDAQ:EXAS), and reduced the price target to …

Roth Capital Remains Bullish On Exact Sciences On The Back Of Cologuard Commercial Launch

Roth Capital analyst Chris Lewis came out today with an update on Exact Sciences Corp (NASDAQ:EXAS), as the company is in the stage of commercialization of …

Canaccord Reiterates Buy On Exact Sciences, Raises PT To $23

In a research note released today, Canaccord analyst Mark Massaro reiterated a Buy rating on Exact Sciences (NASDAQ: EXAS) and raised his price …

Exact Sciences: We Expect Volatility To Continue But Remain Bullish On The Stock, Says William Blair

In a research note issued today, William Blair analyst Brian Weinstein reiterated an Outperform rating on Exact Sciences Corporation (EXAS) ahead of CMS pricing and miscellaneous data points on early …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts